We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $75.05, marking a -1.12% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, added 0.56%.
The pharmaceutical's stock has dropped by 2.92% in the past month, exceeding the Medical sector's loss of 4.4% and lagging the S&P 500's gain of 1.39%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. In that report, analysts expect Astrazeneca to post earnings of $1.03 per share. This would mark year-over-year growth of 18.39%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $13.17 billion, up 14.57% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $4.07 per share and revenue of $52.76 billion, which would represent changes of +12.12% and +15.17%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.35% upward. As of now, Astrazeneca holds a Zacks Rank of #2 (Buy).
Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 18.67. This represents a premium compared to its industry's average Forward P/E of 15.74.
Also, we should mention that AZN has a PEG ratio of 1.4. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.58 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 34, this industry ranks in the top 14% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $75.05, marking a -1.12% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, added 0.56%.
The pharmaceutical's stock has dropped by 2.92% in the past month, exceeding the Medical sector's loss of 4.4% and lagging the S&P 500's gain of 1.39%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. In that report, analysts expect Astrazeneca to post earnings of $1.03 per share. This would mark year-over-year growth of 18.39%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $13.17 billion, up 14.57% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $4.07 per share and revenue of $52.76 billion, which would represent changes of +12.12% and +15.17%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.35% upward. As of now, Astrazeneca holds a Zacks Rank of #2 (Buy).
Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 18.67. This represents a premium compared to its industry's average Forward P/E of 15.74.
Also, we should mention that AZN has a PEG ratio of 1.4. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.58 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 34, this industry ranks in the top 14% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.